Cross-neutralization activity against SARS-CoV-2 is present in currently available intravenous immunoglobulins.

ABSTRACT: Background: Cross-reactivity against human coronaviruses with Flebogamma^® DIF and Gamunex^®-C, two available intravenous immunoglobulins (IVIG), has been reported. In this study, these IVIG were tested for neutralization activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), SARS-CoV and Middle East respiratory syndrome CoV (MERS-CoV). Materials & methods: Neutralization capacity of lots of IVIG manufactured prior to COVID-19 pandemic was assessed against these viruses in cell culture. Infectivity neutralization was quantified by percent reduction in plaque-forming units and/or cytopathic/cytotoxic methods. Results: All IVIG preparations showed neutralization of SARS-CoV-2 isolates. All IVIG lots produced neutralization of S

SUBMITTER: Diez JM 

PROVIDER: S-EPMC7480323 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature